Sept. 14, 2010 Food Industry Specific Patent Application
Medizone International Files Food Industry Specific Patent Application
San Francisco, CA--September 14, 2010--Medizone International, Inc. (OTCBB: MZEI) announced today it has filed a U.S. Provisional patent application covering the use of AsepticSure™ in food processing plants and related facilities for the sterilization of food-borne pathogens such as Listeria, Salmonella and other human harmful, food poisoning-causing bacteria.
Dr. Michael Shannon, Medizone’s Director of Medical Affairs, stated, “The CDC estimates that food-borne illness caused by these and other contaminants affects 76 million people in the United States each year, leading to about 300,000 hospitalizations and 5,000 deaths."
Medizone’s CEO, Edwin Marshall, added, “As with our recent filing covering advanced developments for our bio-terrorism counter measures application of AsepticSure™, this patent application addresses enhancements for use in the food industry. This is one additional step toward building a patent fence around our primary patents that we believe greatly enhances the company’s intellectual property protection. As with our other filings, the claims made in the application are backed up by solid research data achieved in our laboratories in Innovation Park at Queen’s University in Kingston, Ontario, Canada.”
Medizone International, Inc., is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures with additional variants for sports facilities and food processing applications.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
The Eversull Group, Inc.
972-571-1624 / (fax) 214-469-2361
web site: www.medizoneint.com